This page collects WhisperX intelligence signals tagged #oncology. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
The $8 billion acquisition of Loxo Oncology by pharmaceutical giant Eli Lilly began not with a formal negotiation, but with a single white envelope slid across a conference room table. In December 2018, Loxo's leadership expected a casual catch-up with Lilly's head of oncology research. Instead, they walked into a room...
Merck is making a massive $6.7 billion strategic move to secure its oncology future, announcing its intent to acquire Terns Pharmaceuticals. The deal, priced at $53 per share, represents a 6% premium and targets Terns' crown jewel: the promising leukemia treatment TERN-701. This acquisition is a direct response to the ...
Merck is making a massive $6.7 billion bet on the future of cancer treatment, acquiring Terns Pharma in a deal that underscores the intense competition for promising oncology assets. The acquisition values Terns at $53 per share, a 6% premium over its previous closing price, but the real story is the staggering six-fol...
Merck is making a major strategic move to fortify its oncology portfolio, announcing its intent to acquire Terns Pharmaceuticals for $6.7 billion. The deal, priced at $53 per share, represents a 6% premium over Terns' recent closing price and centers on the promising leukemia drug TERN-701. Terns' stock had already sur...
Merck is making a massive $6.7 billion strategic move to acquire Terns Pharmaceuticals, a deal driven by the looming patent expiration of its blockbuster cancer drug, Keytruda. This acquisition is not merely an expansion; it's a critical hedge, granting Merck immediate access to Terns' promising pipeline of treatments ...
Celcuity has laid out a bold commercial forecast, projecting its lead drug candidate, gedatolisib, could achieve up to $2.5 billion in annual peak revenue. This significant financial target is tied directly to the successful execution of the company's ongoing pivotal clinical trials and its parallel preparations for a ...
Novocure has reported a significant success for its Tumor Treating Fields (TTFields) therapy in a mid-stage clinical trial for pancreatic cancer. The positive data from this Phase 2 pilot study marks a critical step for the company's technology in one of the most aggressive and difficult-to-treat solid tumors. The tria...
The European Medicines Agency (EMA) has accepted the marketing authorization application for taletrectinib, a targeted therapy for non-small cell lung cancer (NSCLC) developed by Nuvation Bio and Eisai. This regulatory milestone signals a critical step forward for the drug's potential entry into the European market, pl...
PDS Biotech has signaled a faster route to market for its lead candidate, PDS0101, following a strategic amendment to its pivotal VERSATILE-003 trial protocol. The company now projects a potential Biologics License Application (BLA) submission in the first half of 2025, a timeline accelerated from prior expectations. T...
Caribou Biosciences' stock price surged following a critical regulatory milestone. The U.S. Food and Drug Administration (FDA) granted its CB-010 therapy a Regenerative Medicine Advanced Therapy (RMAT) designation. This status is reserved for regenerative medicine therapies, including cell therapies like CAR-T, that de...
Gilead Sciences is making another major oncology bet, committing over $3 billion to acquire the German biotech Tubulis. The deal, announced Tuesday, includes a $3.15 billion upfront payment and up to an additional $1.85 billion in potential milestone payments. This acquisition is a direct investment in the high-potenti...
A critical diagnostic step is being missed for a vast number of patients with advanced cancer, potentially locking them out of life-extending, targeted treatments. A new study reveals that for most metastatic cancers examined, only about half of patients ever receive genomic sequencing of their tumors—a foundational te...
Gilead Sciences is making a massive strategic move into a fiercely competitive field, agreeing to acquire the private German biotech firm Tubulis in a deal valued at up to $5 billion. This acquisition is a direct and costly bid to rapidly build a dominant position in a cutting-edge and highly sought-after area of oncol...
C4 Therapeutics has inked a new strategic collaboration and license agreement with pharmaceutical giant Roche, focusing on the development of degrader-antibody conjugates (DACs). This deal signals continued validation for C4T's targeted protein degradation platform and deepens its existing partnership with one of the w...
The FDA has delivered a second, decisive rejection to Replimune Group's experimental treatment for advanced melanoma, solidifying the therapy's status as a flashpoint in a high-stakes debate over regulatory standards. This engineered virus, designed to activate the immune system against skin cancer, was initially turne...
The FDA has delivered a second, definitive rejection of Replimune's lead candidate, RP1, sending the company's strategy into crisis and triggering a sharp decline in investor confidence. This is not a request for more data; it is a complete response letter (CRL) that flatly denies the Biologics License Application (BLA...
BeOne has secured a critical regulatory win in China, gaining approval to commercialize Amgen's innovative lung cancer therapy, Imdelltra. This move grants the Chinese biotech firm exclusive rights to market the drug in one of the world's largest oncology markets, marking a significant milestone for both companies. The...
Replimune Group, a clinical-stage biotechnology company, has been hit with a significant setback as the U.S. Food and Drug Administration (FDA) has rejected its cancer drug candidate. This regulatory refusal directly triggers a corporate restructuring, with the company now planning to implement layoffs. The FDA's decis...
GSK is making a high-stakes, aggressive push to reclaim its position in oncology, signaling a major strategic pivot back to a core therapeutic area it had previously deprioritized. The pharmaceutical giant is betting heavily on its late-stage pipeline, accelerating clinical trials for key cancer drugs in a bid to drive...
Replimune Group Inc. faces a severe market crisis as its shares collapsed by 56% in a single session, extending prior losses. The catalyst is a decisive and damaging regulatory blow: the U.S. Food and Drug Administration (FDA) has issued a complete response letter rejecting the company's lead candidate, RP1, for the tr...